159 related articles for article (PubMed ID: 12793013)
1. [Development of bladder cancer chemoprevention].
Dai G; Wang X
Wei Sheng Yan Jiu; 2003 Mar; 32(2):159-62. PubMed ID: 12793013
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of superficial bladder cancer.
Kamat AM
Expert Rev Anticancer Ther; 2003 Dec; 3(6):799-808. PubMed ID: 14686702
[TBL] [Abstract][Full Text] [Related]
3. Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
Okajima E; Uemura H; Ohnishi S; Tanaka M; Ohta M; Tani M; Fujimoto K; Ozono S; Okajima E; Hirao Y
Aktuelle Urol; 2003 Jul; 34(4):256-8. PubMed ID: 14566678
[TBL] [Abstract][Full Text] [Related]
4. Potential chemoprevention effect of dietary fucoxanthin on urinary bladder cancer EJ-1 cell line.
Zhang Z; Zhang P; Hamada M; Takahashi S; Xing G; Liu J; Sugiura N
Oncol Rep; 2008 Nov; 20(5):1099-103. PubMed ID: 18949407
[TBL] [Abstract][Full Text] [Related]
5. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.
Sabichi AL; Lerner SP; Atkinson EN; Grossman HB; Caraway NP; Dinney CP; Penson DF; Matin S; Kamat A; Pisters LL; Lin DW; Katz RL; Brenner DE; Hemstreet GP; Wargo M; Bleyer A; Sanders WH; Clifford JL; Parnes HL; Lippman SM
Clin Cancer Res; 2008 Jan; 14(1):224-9. PubMed ID: 18172274
[TBL] [Abstract][Full Text] [Related]
6. Watchful waiting for low-grade Ta bladder tumours: the idea would have been unacceptable 30 years ago, but nowadays we are highly interested in the results of this study exploring it.
Oosterlinck W
Eur Urol; 2006 Feb; 49(2):215-6. PubMed ID: 16426733
[No Abstract] [Full Text] [Related]
7. Retinoids in the prevention of bladder cancer.
Nutting CM; Huddart RA
Expert Rev Anticancer Ther; 2001 Dec; 1(4):541-5. PubMed ID: 12113086
[TBL] [Abstract][Full Text] [Related]
8. Re: Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients.
Atan A; Basar MM
J Urol; 1999 Nov; 162(5):1706. PubMed ID: 10524913
[No Abstract] [Full Text] [Related]
9. Retinoid receptor mRNA expression profiles in human bladder cancer specimens.
Boorjian S; Scherr DS; Mongan NP; Zhuang Y; Nanus DM; Gudas LJ
Int J Oncol; 2005 Apr; 26(4):1041-8. PubMed ID: 15754000
[TBL] [Abstract][Full Text] [Related]
10. The use of chemotherapeutic agents in the prophylaxis of papillary bladder tumours.
Pavone-Macaluso M; Caramia G; Rizzo FP
Urol Int; 1971; 26(5):379-87. PubMed ID: 5136749
[No Abstract] [Full Text] [Related]
11. [Intravesical therapy: Influence on superficial bladder cancer recurrence].
García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; González Alvarez RC; Jalón Monzón A; Martínez Gómez FJ; Sánchez Trilla A; Regadera Sejas J
Arch Esp Urol; 2007; 60(1):36-43. PubMed ID: 17408170
[TBL] [Abstract][Full Text] [Related]
12. Urinary bladder cancer: mechanisms of development and progression.
Kroft SH; Oyasu R
Lab Invest; 1994 Aug; 71(2):158-74. PubMed ID: 8078295
[No Abstract] [Full Text] [Related]
13. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy.
Yoshida S; Saito K; Koga F; Yokoyama M; Kageyama Y; Masuda H; Kobayashi T; Kawakami S; Kihara K
BJU Int; 2008 Apr; 101(8):978-81. PubMed ID: 18190628
[TBL] [Abstract][Full Text] [Related]
15. Intravesical chemotherapy--other agents.
Smith PH; Cruickshank J; Hetherington JW
Prog Clin Biol Res; 1984; 162B():173-9. PubMed ID: 6504895
[No Abstract] [Full Text] [Related]
16. Epigenetic biomarkers in urothelial bladder cancer.
Kim WJ; Kim YJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
[TBL] [Abstract][Full Text] [Related]
17. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
18. Results with radical cystectomy for treating bladder cancer: a 'reference standard' for high-grade, invasive bladder cancer.
Stein JP; Skinner DG
BJU Int; 2003 Jul; 92(1):12-7. PubMed ID: 12823375
[No Abstract] [Full Text] [Related]
19. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer.
Messing E; Kim KM; Sharkey F; Schultz M; Parnes H; Kim D; Saltzstein D; Wilding G
J Urol; 2006 Aug; 176(2):500-4. PubMed ID: 16813878
[TBL] [Abstract][Full Text] [Related]
20. Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors?
Oosterlinck W; Sylvester R; Babjuk M; Kaasinen E; Böhle A; Palou-Redorta J; Rouprêt M;
Eur Urol; 2011 Mar; 59(3):374-6. PubMed ID: 21168952
[No Abstract] [Full Text] [Related]
[Next] [New Search]
